Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia
(2010) In Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis 34(3). p.335-339- Abstract
- The 309T>G polymorphism in the promoter region of the MDM2 gene, known as SNP309, has recently been suggested as an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL) although this has been questioned. To investigate this further, we analyzed the MDM2 SNP309 genotypes in 418 CLL patients and correlated the results with established CLL prognostic factors, time to treatment and overall survival. In this Swedish cohort, no association existed between any particular MDM2 SNP309 genotype, overall survival and time to treatment. Furthermore, no correlation was shown between the MDM2 SNP309 genotypes and Binet stage, IGHV mutational status and recurrent genomic aberrations. In summary, this study argues against the use of the... (More)
- The 309T>G polymorphism in the promoter region of the MDM2 gene, known as SNP309, has recently been suggested as an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL) although this has been questioned. To investigate this further, we analyzed the MDM2 SNP309 genotypes in 418 CLL patients and correlated the results with established CLL prognostic factors, time to treatment and overall survival. In this Swedish cohort, no association existed between any particular MDM2 SNP309 genotype, overall survival and time to treatment. Furthermore, no correlation was shown between the MDM2 SNP309 genotypes and Binet stage, IGHV mutational status and recurrent genomic aberrations. In summary, this study argues against the use of the MDM2 SNP309 as a prognostic marker in CLL. (C) 2009 Elsevier Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1568854
- author
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Genomic aberrations, Prognostic markers, status, IGHV mutational, Binet stage, MDM2 SNP309, Chronic lymphocytic leukemia
- in
- Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis
- volume
- 34
- issue
- 3
- pages
- 335 - 339
- publisher
- Elsevier
- external identifiers
-
- wos:000274529600013
- scopus:77649181649
- pmid:19573916
- ISSN
- 1873-5835
- DOI
- 10.1016/j.leukres.2009.06.006
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Hematology/Transplantation (013022014)
- id
- 06e35f4d-139f-4264-8827-7e9996460d7c (old id 1568854)
- date added to LUP
- 2016-04-01 11:14:24
- date last changed
- 2022-01-26 06:24:28
@article{06e35f4d-139f-4264-8827-7e9996460d7c, abstract = {{The 309T>G polymorphism in the promoter region of the MDM2 gene, known as SNP309, has recently been suggested as an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL) although this has been questioned. To investigate this further, we analyzed the MDM2 SNP309 genotypes in 418 CLL patients and correlated the results with established CLL prognostic factors, time to treatment and overall survival. In this Swedish cohort, no association existed between any particular MDM2 SNP309 genotype, overall survival and time to treatment. Furthermore, no correlation was shown between the MDM2 SNP309 genotypes and Binet stage, IGHV mutational status and recurrent genomic aberrations. In summary, this study argues against the use of the MDM2 SNP309 as a prognostic marker in CLL. (C) 2009 Elsevier Ltd. All rights reserved.}}, author = {{Kaderi, Mohd Arifin and Mansouri, Mahmoud and Zainuddin, Norafiza and Cahill, Nicola and Gunnarsson, Rebeqa and Jansson, Mattias and Kimby, Eva and Aleskog, Anna and Lundin, Jeanette and Glimelius, Bengt and Melbye, Mads and Juliusson, Gunnar and Jurlander, Jesper and Rosenquist, Richard}}, issn = {{1873-5835}}, keywords = {{Genomic aberrations; Prognostic markers; status; IGHV mutational; Binet stage; MDM2 SNP309; Chronic lymphocytic leukemia}}, language = {{eng}}, number = {{3}}, pages = {{335--339}}, publisher = {{Elsevier}}, series = {{Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis}}, title = {{Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia}}, url = {{http://dx.doi.org/10.1016/j.leukres.2009.06.006}}, doi = {{10.1016/j.leukres.2009.06.006}}, volume = {{34}}, year = {{2010}}, }